The metamorphosis of hydromorphone

Gary M. Reisfield, MD, George R. Wilson, MD





Full Text:



Sarhill N, Walsh D, Nelson KA: Hydromorphone: Pharmacology and clinical applications in cancer patients. Support Care Cancer. 2001; 9: 84-96.

Booth M: Opium: A history. New York: St. Martin’s Press, 1996: 201.

Meier B: Pain Killer: A Wonder Drug’s Trail of Addiction and Death. Emmaus, PA: Rodale, 2003: 88.

Eddy NB: Dilaudid (hydromorphinone hydrochloride). JAMA. 1933; 100(13): 1032-1033.

David NA: Dilaudid and morphine effects on basal metabolism and other body functions. JAMA. 1934; 103(7): 474-478.

Nathanson IT, Daland EM: The use of dilaudid in treating patients with cancer. N Engl J Med. 1935;213(16):741-746.

Stroud CM: The use of Dilaudid in the pain of cancer. JAMA. 1934; 103(19): 1421-1424.

Council on Pharmacy and Chemistry. Preliminary reports of the council. Dilaudid. JAMA. 1933; 100(13): 1031-1032.

Eddy NB, May EL: The search for a better analgesic. Science. 1973; 181: 407-414.

Hanna C, Mazuzan JE, Abajian J: An evaluation of dihydromorphinone in treating postoperative pain. Anesth Analg. 1962; 41(6): 755-761.

Goldman AH: Elvis. New York: McGraw-Hill, 1981: 556-560.

Szasz T: Therapeutic state—Unequal justice for all. Available online at Accessed 11/4/04.

Kane: A tiny yellow piece of heaven. Hydromorphone (Dilaudid). Available online at Accessed 10/11/04.

ILLadvised: I can see why it is so addictive. Hydromorphone. Available online at Accessed 10/11/04.

McBride DC, McCoy CB, Rivers JE, et al.: Dilaudid use: Trends and characteristics of users. Chem Depend. 1980; 4(2): 85-100.

Lindberg DK: A word of warning. Marked increase in hydromorphone (Dilaudid) addiction. J Florida Med Assoc. 1978; 65(10): 822.

Lindberg DK: How the addict gets his prescription. J Florida Med Assoc. 1984; 71(4): 240-242

Drugs and chemicals of concern. Hydromorphone. US Department of Justice, Drug Enforcement Administration, Diversion Control Program. Available online at Accessed 10/7/04.

Narcanon Southern California. Available online at

Drug Intelligence Brief. Oxycontin: Pharmaceutical diversion, March 2002. Available online at Accessed 3/22/05.

Gilson AM, Ryan KM, Joranson DE, et al.: A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997-2002. J Pain Symptom Manage. 2004; 28(2): 176-188.

Lavoie LO: Generic short acting hydromorphone vs. Dilaudid. College Newsletter: A Publication of the College of Physicians and Surgeons of Saskatchewan. 2004; 20(57): 8-9.

Joranson DE, Ryan KM, Gilson AM, et al.: Trends in medical use and abuse of opioid analgesics. JAMA. 2000; 283(13): 1710-1714.

Scholz J, Steinfath M, Koch C, et al.: The pharmacologic basis of potoperative pain therapy. Epidural opioid administration. Anaesthetist. 1997; 46 (Suppl 3):S154-S158.

Anderson VC, Cooke B, Burchiel KJ: Intrathecal hydromorphone for chronic nonmalignant pain: A retrospective study. Pain Medicine. 2001; 2(4): 287-297.

Sarhill N, Walsh D, Khawam E, et al.: Nebulized hydromorphone for dyspnea in hospice care of advanced cancer. Am J Hosp Palliat Care. 2000; 17(6): 389-391.

Rudy AC, Coda BA, Archer SM, et al.: A multiple-dose phase I study of intranasal hydromorphone hydrochloride in health volunteers. Anesth Analg. 2004; 99(5): 1379-1386.

Babul N, Darke AC: Putative role of hydromorphone metabolites in myoclonus (Letter). Pain. 1992; 51(2): 260-261.

Palladone XL product monograph (Canadian-approved label). Purdue Pharma, LP, 6/16/99, revised 2/28/02.

Smith MT: Neuroexcitatory effects of morphine and hydromorphone: Evidence implicating the 3-glucuronide metabolites. Clin Exp Pharmacol Physiol. 2000; 27: 524-528.

Wright AWE, Mather LE, Smith MT: Hydromorphone-3-glucuronide a more potent neuro-excitant than its structural analogue, morphine-3-glucuronide. Life Sci. 2001; 69: 409-420.

Babul N, Darke AC, Hagen N: Hydromorphone metabolite accumulation in renal failure (letter). J Pain Symptom Manage 1995; 10(3): 184-186.

Sarhill N, Walsh D, Nelson KA: Hydromorphone: Pharmacology and clinical applications in cancer patients. Support Care Cancer. 2001; 9: 84-96.

Hutchinson MR, Menelaou A, Foster DJR, et al.: CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol. 2003; 57(3): 287-297.

Otton SV, Schadel M, Cheung SW, et al.: CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin Pharmacol Ther. 1993; 54(5): 463-472.

Armstrong SC, Cozza KL: Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: Theory and clinical reality, part I. Psychosomatics. 2003; 44(2): 167-171.

DeStoutz ND, Bruera E, Suarez-Almazor M: Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage. 1995; 10(5): 378-384.

Lee MA, Leng ME, Tiernan EJ: Retrospective study of the use of Hydromorphone in palliative care patients with normal and abnormal urea and creatinine. Palliat Med. 2001; 15(1): 26-34.

Dean M: Opioids in renal failure and dialysis patients. J Pain Symptom Manage. 2004; 28(5): 497-504.

Jasinski DR, Pevnick JS, Clark SC, et al.: Therapeutic usefulness of propoxyphene napsylate in narcotic addiction. Arch Gen Psychiatry. 1977; 34(2): 227-233.

Hill, JL, Zacny JP: Comparing the subjective, psychomotor, and physiological effects of intravenous hydromorphone and morphine in healthy volunteers. Psychopharmacology. 2000; 152: 31-39.

Quinn DI, Wodak A, Day RO: Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users. Clin Pharmacokin. 1997; 33(5): 344-400.

Ferrell B, Wisdom C, Wenzl C, et al.: Effects of controlledrelease morphine on quality of life for cancer pain. Oncol Nurs Forum. 1989; 16: 521-526.

Palangio M, Northfelt DW, Portenoy RK, et al.: Dose conversion and titration with a novel, once-daily OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain. J Pain Symptom Manage. 2002; 23(5): 355-368.

Angst MS, Drover DR, Lotsch J, et al.: Pharmacodynamics of orally administered sustained-release hydromorphone in humans. Anesthesiology. 2001; 94: 63-73.

Hays H, Hagen N, Thirwell M, et al.: Comparative clinical efficacy and safety of immediate release and controlled release hydromorphone for chronic severe cancer pain. Cancer. 1994; 74(6): 1808-1816.

Bruera E, Sloan P, Mount B, et al.: A randomized, doubleblind, double dummy, crossover trial comparing the safety and efficacy of oral sustained-release hydromorphone with immediate-release Hydromorphone in patients with cancer pain. Canadian Palliative Care Clinical Trials Group. J Clin Oncol. 1996; 14(5): 1713-1717.

Weinstein SM, Grosset AB, Roberts MS, et al.: Two double blind randomized trials of once-a-day controlled release oral hydromorphone (Palladone XL) compared to immediate release hydromorphone dosed QID. American Pain Society Annual Meeting poster #645. Available online at Accessed 10/25/04.

Hagen NA, Babul N: Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone formulation in the treatment of cancer pain. Cancer. 1997; 79(7): 1428-1437.

FDA talk paper. FDA approves new extended release pain medication: Agency works with sponsor to develop an effective plan to reduce inappropriate use. Available online at Accessed 10/11/04.

Purdue begins shipment of Palladone (hydromorphone HCl extended-release) capsules (CII). Available online at Accessed 1/24/05.

Purdue Pharma, LP: Palladone package insert.



  • There are currently no refbacks.